Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

so developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, the upcoming webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 An increase of awareness related ... forms of food nutrients, regulatory changes and concerns related ... in demand for natural astaxanthin over the past few ... up their capacities to satisfy the rising demand. ... source astaxanthin (used in nutraceuticals, aqua feed, food and ...
(Date:3/25/2015)... Having added two International locations in ... 2014, ITRA Global proudly announced recently the organization’s expansion ... Alliance, based in the United States, is one of ... of commercial real estate. , Saltwood International ... that exclusively advises occupiers of office space, ensuring that ...
(Date:3/25/2015)... March 25, 2015  The Technology Association of ... dedicated to the promotion and economic advancement of ... Health as one of its Top 40 Innovative Technology ... recognize this prestigious group at the 2015 Georgia Technology ... Galleria Centre. TAG,S Top 40 Awards recognize ...
(Date:3/25/2015)... , March 25, 2015 ... today version 4 of Face2Gene, allowing geneticists ... from computers, as well as mobile devices. Face2Gene® facilitates ... human malformations to present comprehensive and up-to-date genetic references. ... Clinical Genetics Meeting, ACMG 2015, in Salt ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2International Organization Expands its Global Reach to Warsaw, Poland 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... Lines for Assay Development, Biomarker Identification ... and ADME/Tox ... Bulletin Board: MCET), entered into a worldwide,exclusive license and technology ... Fa2N-4 immortalized,adult human liver cell lines. Corning paid MultiCell ...
... protection ... Fla., Oct. 10 Union Springs Pharmaceuticals,LLC, announced today at ... product, MyClyns(TM). MyClyns is the first product of its,kind to ... in the field when exposed to harmful pathogens. The product, ...
... DermTech International, Inc.,a biotechnology company developing ... melanoma and other diseases, today appointed John ... Dr. Quackenbush is a,Professor of Biostatistics and ... Professor of Computational Biology and Bioinformatics,at the ...
Cached Biology Technology:MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3MyClyns(TM), a New Standard of Personal Protection, is Announced at the EMS and Firehouse Central EXPO 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... took place in Florence last week. It provided us with some ... Did life begin on Mars rather than on earth?, ... "Terror Bird", was probably a herbivore Goldschmidt2014 is ... June, 2014, so if you want to attend, put the dates ...
... estimate that there is a minimum of 320,000 viruses in ... a majority of them, they say, could provide information critical ... This undertaking would cost approximately $6.3 billion, or $1.4 billion ... fraction of the economic impact of a major pandemic like ...
... Candida albicans is a common fungus found living in, ... species causes no harm to humans unless it can breach ... or death. It is known as an opportunistic pathogen that ... New research, presented today at the Society for General Microbiology,s ...
Cached Biology News:First estimate of total viruses in mammals 2First estimate of total viruses in mammals 3First estimate of total viruses in mammals 4Research identifies how mouth cells resist Candida infection 2
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: